Download App

Log in to access Online Inquiry
Company Overview More
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company’s lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.
CEO: --
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Moomoo > Quotes > CNTB Connect Biopharma > Detailed Quotes

CNTB Connect Biopharma

0.900+0.047+5.51%
Trading Session 05/19 13:58 ET
High
0.960
Open
0.878
Turnover
207.22K
Low
0.810
Pre Close
0.853
Volume
233.88K
Market Cap
49.57M
P/E(TTM)
Loss
52wk High
29.274
Shares
55.08M
P/E(Static)
Loss
52wk Low
0.557
Float Cap
16.81M
Bid/Ask %
-33.33%
Historical High
29.274
Shs Float
18.67M
Volume Ratio
0.70
Historical Low
0.557
Dividend TTM
--
Div Yield TTM
--
P/B
0.18
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.25%
Amplitude
17.63%
Avg Price
0.886
Lot Size
1
Float Cap
16.81M
Bid/Ask %
-33.33%
Historical High
29.274
Shs Float
18.67M
Volume Ratio
0.70
Historical Low
0.557
Dividend TTM
--
P/B
0.18
Dividend LFY
--
Turnover Ratio
1.25%
Amplitude
17.63%
Avg Price
0.886
Lot Size
1
Price Forecast

No Data

News

Comment